Summary

Plasma Derived Therapy Trends and Forecast
The future of the global plasma derived therapy market looks promising with opportunities in the hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura markets. The global plasma derived therapy market is expected to grow with a CAGR of 7.2% from 2024 to 2030. The major drivers for this market are rising rates of unusual and chronic diseases within the population, growing demand in developing countries for medications made from plasma, along with the rapid research and development programs by the government.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Plasma Derived Therapy by Segment
The study includes a forecast for the global plasma derived therapy by product, application, and region.

Plasma Derived Therapy Market by Product [Shipment Analysis by Value from 2018 to 2030]:
• Immunoglobulin
• Coagulation Factor
• Albumin
• Others

Plasma Derived Therapy Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Hemophilia
• Primary Immunodeficiency Disease
• Idiopathic Thrombocytopenic Purpura
• Others

Plasma Derived Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Plasma Derived Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies plasma derived therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasma derived therapy companies profiled in this report include-
• CSL Behring
• Takeda Pharmaceutical
• BPL
• ADMA Biologics
• Biotest
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• Pfizer

Plasma Derived Therapy Market Insights
Lucintel forecasts that immunoglobulin is expected to witness the highest growth over the forecast period due to rise in use of immunoglobulins for the treatment of several complex diseases.

North America is expected to witness highest growth over the forecast period due to significant initiatives to support the therapeutic system from the government and corporate sector, and the number of plasma collecting units in this business has expanded dramatically in recent years, leading to a substantial increase in market size.

Features of the Global Plasma Derived Therapy Market

Market Size Estimates: Plasma derived therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Plasma derived therapy market size by product, application, and region in terms of value ($B).
Regional Analysis: Plasma derived therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product, application, and regions for the plasma derived therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plasma derived therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ




Q1. What is the growth forecast for plasma derived therapy market?
Answer: The global plasma derived therapy market is expected to grow with a CAGR of 7.2% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the plasma derived therapy market?
Answer: The major drivers for this market are rising rates of unusual and chronic diseases within the population, growing demand in developing countries for medications made from plasma, along with the rapid research and development programs by the government.

Q3. What are the major segments for plasma derived therapy market?
Answer: The future of the global plasma derived therapy market looks promising with opportunities in the hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura markets.

Q4. Who are the key plasma derived therapy market companies?
Answer: Some of the key plasma derived therapy companies are as follows:
• CSL Behring
• Takeda Pharmaceutical
• BPL
• ADMA Biologics
• Biotest
• Octapharma
• Grifols
• Kamada Pharmaceuticals
• SK Plasma
• Pfizer



Q5. Which plasma derived therapy market segment will be the largest in future?
Answer: Lucintel forecasts that immunoglobulin is expected to witness the highest growth over the forecast period due to rise in use of immunoglobulins for the treatment of several complex diseases.

Q6. In plasma derived therapy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to significant initiatives to support the therapeutic system from the government and corporate sector, and the number of plasma collecting units in this business has expanded dramatically in recent years, leading to a substantial increase in market size.

Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the plasma derived therapy market by product (immunoglobulin, coagulation factor, albumin, and others), application (hemophilia, primary immunodeficiency disease, idiopathic thrombocytopenic purpura, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

ページTOPに戻る

Table of Contents

Table of Contents

1. Executive Summary

2. Global Plasma Derived Therapy Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Plasma Derived Therapy Market Trends (2018-2023) and Forecast (2024-2030)

3.3: Global Plasma Derived Therapy Market by Product
3.3.1: Immunoglobulin
3.3.2: Coagulation factor
3.3.3: Albumin
3.3.4: Others






3.4: Global Plasma Derived Therapy Market by Application
3.4.1: Hemophilia
3.4.2: Primary immunodeficiency disease
3.4.3: Idiopathic thrombocytopenic purpura
3.4.4: Others

















4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Plasma Derived Therapy Market by Region
4.2: North American Plasma Derived Therapy Market
4.2.1: North American Plasma Derived Therapy Market by Product: Immunoglobulin, Coagulation factor, Albumin, and Others
4.2.2: North American Plasma Derived Therapy Market by Application: Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, and Others



4.3: European Plasma Derived Therapy Market
4.3.1: European Plasma Derived Therapy Market by Product: Immunoglobulin, Coagulation factor, Albumin, and Others
4.3.2: European Plasma Derived Therapy Market by Application: Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, and Others



4.4: APAC Plasma Derived Therapy Market
4.4.1: APAC Plasma Derived Therapy Market by Product: Immunoglobulin, Coagulation factor, Albumin, and Others
4.4.2: APAC Plasma Derived Therapy Market by Application: Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, and Others



4.5: ROW Plasma Derived Therapy Market
4.5.1: ROW Plasma Derived Therapy Market by Product: Immunoglobulin, Coagulation factor, Albumin, and Others
4.5.2: ROW Plasma Derived Therapy Market by Application: Hemophilia, Primary immunodeficiency disease, Idiopathic thrombocytopenic purpura, and Others



5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis

6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Plasma Derived Therapy Market by Product
6.1.2: Growth Opportunities for the Global Plasma Derived Therapy Market by Application
6.1.3: Growth Opportunities for the Global Plasma Derived Therapy Market by Region

6.2: Emerging Trends in the Global Plasma Derived Therapy Market

6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Plasma Derived Therapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Plasma Derived Therapy Market
6.3.4: Certification and Licensing

7. Company Profiles of Leading Players
7.1: CSL Behring
7.2: Takeda Pharmaceutical
7.3: BPL
7.4: ADMA Biologics
7.5: Biotest
7.6: Octapharma
7.7: Grifols
7.8: Kamada Pharmaceuticals
7.9: SK Plasma
7.10: Pfizer